• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions
【24h】

Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions

机译：精神分裂症的心脏代谢风险和干预方向，3：心理药理学干预

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with schizophrenia have increased prevalence rates for many cardiometabolic risk factors; the prevalence and severity of these risks increase after the institution of antipsychotic medication. Nearly 2 dozen different pharmacologic interventions have been trialed to prevent or attenuate antipsychotic-related cardiometabolic changes. Metformin (usually 1,000-1,500 mg/d) has emerged as the best-studied intervention; in short-and intermediateduration randomized controlled trials, it has been shown to bring about improvements in weight and other anthropometric indices, in fasting sugar and other glycemic control indices, and in total cholesterol and other lipid metabolism indices. Topiramate and aripiprazole are other possible interventions with support in literature; besides improving metabolic outcomes, these drugs may improve indices of psychopathology, as well. Encouraging though the findings are, there are many unanswered questions that require attention in future research. (C) Copyright 2016 Physicians Postgraduate Press, Inc.
机译：精神分裂症患者的许多心脏代谢危险因素的患病率增加;服用抗精神病药物后，这些风险的发生率和严重性增加。已经尝试了近2种不同的药物干预措施，以预防或减弱抗精神病相关的心脏代谢变化。二甲双胍（通常为1,000-1,500 mg / d）已成为研究最多的干预措施。在短期和中期的随机对照试验中，已证明可以改善体重和其他人体测量指标，空腹糖和其他血糖控制指标以及总胆固醇和其他脂质代谢指标。托吡酯和阿立哌唑是在文献支持下的其他可能干预措施。除了改善代谢结果外，这些药物还可以改善心理病理学指标。尽管发现令人鼓舞，但仍有许多未解决的问题需要在未来的研究中予以关注。 （C）版权所有2016 Physicians Postgraduate Press，Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号